Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies

Steen, Nele Van Der; Garajová, Ingrid; Rolfo, Christian; Cavazzoni, Andrea; Giovannetti, Elisa

doi:10.1016/b978-0-12-813753-6.00002-0

“…Rilotumumab and obinutuzumab are two drugs that target the HGF c-Met pathway. Rilotumumab is a fully humanized monoclonal antibody that inhibits the interaction between hepatocyte growth factor (HGF) and c-Met, thereby blocking c-Met activation and tumor development [73]. Obinutuzumab, on the other hand, is a humanized anti-MET antibody that prevents MET from binding to HGF [3].…”

Section: Rilotumumab and Obinutuzumabmentioning

confidence: 99%

Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies

Panda

¹

,

Verma

²

,

Lakkakula

³

2023

Onco

1

0

View full text Add to dashboard Cite

Esophageal cancer is a formidable challenge in the realm of cancer treatment. Conventional methods such as surgery, chemotherapy, and immunotherapy have demonstrated limited success rates in managing this disease. In response, targeted drug therapies have emerged as a promising strategy to improve outcomes for patients. These therapies aim to disrupt specific pathways involved in the growth and development of esophageal cancer cells. This review explores various drugs used to target specific pathways, including cetuximab and monoclonal antibodies (gefitinib) that target the epidermal growth factor receptor (EGFR), trastuzumab that targets human epidermal growth factor receptor 2 (HER-2), drugs targeting the vascular endothelial growth factor receptor (VEGFR), mTOR inhibitors, and cMET inhibitors. Additionally, the article discusses the impact of drug resistance on the effectiveness of these therapies, highlighting factors such as cancer stem cells, cancer-associated fibroblasts, immune-inflammatory cells, cytokines, hypoxia, and growth factors. While drug targeting approaches do not provide a complete cure for esophageal cancer due to drug resistance and associated side effects, they offer potential for improving patient survival rates.

show abstract

“…Rilotumumab and obinutuzumab are two drugs that target the HGF c-Met pathway. Rilotumumab is a fully humanized monoclonal antibody that inhibits the interaction between hepatocyte growth factor (HGF) and c-Met, thereby blocking c-Met activation and tumor development [73]. Obinutuzumab, on the other hand, is a humanized anti-MET antibody that prevents MET from binding to HGF [22].…”

Section: Rilotumumab and Obinutuzumabmentioning

confidence: 99%

Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies"

Verma¹,

Panda²,

Lvks³

2023

Preprint

0

View full text Add to dashboard Cite

Esophageal cancer is a formidable challenge in the realm of cancer treatment. Conventional methods such as surgery, chemotherapy, and immunotherapy have demonstrated limited success rates in managing this disease. In response, targeted drug therapies have emerged as a promising strategy to improve outcomes for patients. These therapies aim to disrupt specific pathways involved in the growth and development of esophageal cancer cells. This review explores various drugs used to target specific pathways, including cetuximab and monoclonal antibodies (gefitinib) that target the epidermal growth factor receptor (EGFR), trastuzumab that targets human epidermal growth factor receptor 2 (HER-2), drugs targeting the vascular endothelial growth factor receptor (VEGFR), mTOR inhibitors, and cMET inhibitors. Additionally, the article discusses the impact of drug resistance on the effectiveness of these therapies, highlighting factors such as cancer stem cells, cancer-associated fibroblasts, immune-inflammatory cells, cytokines, hypoxia, and growth factors. While drug targeting approaches do not provide a complete cure for esophageal cancer due to drug resistance and associated side effects, they offer potential for improving patient survival rates.

show abstract

Application of C-MET Inhibitors in the Treatment of Non-small Cell Lung Cancer

Zhou¹

2022

HSET

0

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is a kind of refractory lung cancer. Under traditional cisplatin treatment, it is difficult for patients, especially the advanced cancer patients, to have a high cure rate and survival rate. Abnormal histological variants may lead to NSCLC. Mutations in C-MET may lead to abnormal downstream metabolism, which in turn triggers unrestricted cell growth and metastasis. Therefore, C-MET inhibitors can inhibitive the overexpression and activation of C-MET by blocking the gene pathway, in result in that the growth and the spread of cancer cell can be inhibitived. A variety of C-MET inhibitors such as crizotinib, cabonitinib, capmatinib, etc., have been found to have good therapeutic activity and considerable clinical data. This paper discussed the C-MET as a therapeutic target in NSCLC, and outline the applications in clinical and therapeutic effects of various C-MET inhibitors.

show abstract

Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies

Cited by 4 publications

References 258 publications

Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies

Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies

Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies"

Application of C-MET Inhibitors in the Treatment of Non-small Cell Lung Cancer

Contact Info

Product

Resources

About